ArticleSurgery today2026
Clinical presentation and staged multidisciplinary management of aortoesophageal fistula.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposesTo describe the clinical presentation, staged management strategies, and the outcomes of patients with aortoesophageal fistula (AEF) in a single-center institutional series.
methodsWe retrospectively reviewed confirmed AEF cases treated at our institution between 2009 and 2023. The cases were described according to etiology, clinical presentation, baseline severity, prior aortic intervention, treatment pathway, and outcomes.
resultsEighteen patients were included: 13 with primary AEF and 5 with secondary post-TEVAR. The most frequent presenting symptoms were hematemesis, often accompanied by chest pain, melena, or fever. Contrast-enhanced CT or computed tomography angiography (CTA) is the primary diagnostic modality. TEVAR is frequently used as an initial strategy for hemorrhage control. Multidisciplinary management, including operative control, anti-infective therapy, and nutritional support, is commonly used to manage these patients.
conclusionsIn our cohort, CTA was commonly used as the primary diagnostic modality for suspected AEF, and TEVAR was the initial strategy for hemorrhage control. Management in this cohort often involved staged multidisciplinary coordination, focusing on hemostasis, infection control, and delayed reconstruction. These findings should be interpreted as descriptive and hypothesis-generating.
Indexed as
Identifiers
42525083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.